Guided Therapeutics (OTCMKTS:GTHP) and Omeros (NASDAQ:OMER) Head to Head Survey

Guided Therapeutics (OTCMKTS:GTHP) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, institutional ownership, dividends, valuation and risk.

Risk and Volatility

Guided Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.55, meaning that its stock price is 155% more volatile than the S&P 500.

Profitability

This table compares Guided Therapeutics and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-274.24%
Omeros	N/A	-102.16%	64.87%

Earnings and Valuation

This table compares Guided Therapeutics and Omeros”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$770,000.00	37.61	-$3.20 million	($0.04)	-7.50
Omeros	$9.89 million	87.28	-$3.35 million	$0.70	17.04

Guided Therapeutics has higher earnings, but lower revenue than Omeros. Guided Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Guided Therapeutics and Omeros, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	0.00
Omeros	1	2	2	1	2.50

Omeros has a consensus target price of $38.00, suggesting a potential upside of 218.52%. Given Omeros’ stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Guided Therapeutics.

Institutional & Insider Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Omeros beats Guided Therapeutics on 11 of the 14 factors compared between the two stocks.

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.